WO2005084255A2 - Timbre transdermique d'aspirine - Google Patents

Timbre transdermique d'aspirine Download PDF

Info

Publication number
WO2005084255A2
WO2005084255A2 PCT/US2005/006297 US2005006297W WO2005084255A2 WO 2005084255 A2 WO2005084255 A2 WO 2005084255A2 US 2005006297 W US2005006297 W US 2005006297W WO 2005084255 A2 WO2005084255 A2 WO 2005084255A2
Authority
WO
WIPO (PCT)
Prior art keywords
aspirin
layer
patch
transdermal
vapor
Prior art date
Application number
PCT/US2005/006297
Other languages
English (en)
Other versions
WO2005084255A3 (fr
Inventor
Alec D. Keith
Original Assignee
Keith Alec D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keith Alec D filed Critical Keith Alec D
Publication of WO2005084255A2 publication Critical patent/WO2005084255A2/fr
Publication of WO2005084255A3 publication Critical patent/WO2005084255A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid

Definitions

  • the present invention relates to a novel way of introducing aspirin into the bloodstream. More particularly, the present invention is a transdermal patch containing aspirin for use by individuals concerned with avoiding the gastrointestinal effects of aspirin. Description of Related Art
  • Aspirin is an effective antithrombotic agent in patients with cerebrovascular disease and ischemic heart disease. Aspirin irreversibly acetylates the enzyme cyclo-oxygenase found in platelets and vascular wall cells. Cyclo-oxygenase converts arachidonic acid to thromboxane-A2 (TXA2) in platelets and to prostaglandin-I2 (PGI2 or prostacyclin) in vascular walls. TXA2 induces platelet aggregation and vasoconstriction, while PGI2 inhibits platelet aggregation and induces vasodilation. Thus, one of the benefits of aspirin therapy is its effects on increasing PGI2 synthesis.
  • Aspirin is also useful for pain relief because it inhibits prostaglandin synthesis and the reduction of fever via action on the heat-regulating center of the hypothalamus.
  • Aspirin is also useful for pain relief because it inhibits prostaglandin synthesis and the reduction of fever via action on the heat-regulating center of the hypothalamus.
  • palpable gastrointestinal side effects such as nausea, vomiting, dyspepsia, epigastric discomfort, heartburn, and stomach pains. These side effects are caused by the well- documented effects that aspirin has on the gastrointestinal lining of the stomach. Aspirin is a major culprit in causing stomach ulcers and gastrointestinal bleeding due to the corrosive effects of aspirin, even in rr ⁇ nimal doses, on the stomach.
  • Fig. 1 is a plan view of the dermal side of the aspirin transdermal patch assembly of the present invention
  • Fig. 2 is a sectional view taken on line a-a of Fig. 1;
  • Fig. 3 is a sectional view taken on line b-b of Fig 1; and
  • Fig. 4 is a plan view of the dermal side of an alternative embodiment of the aspirin transdermal patch assembly of the present invention. DESCRIPTION OF THE PREFERRED EMBODIMENT(S) [0014]
  • Figs. 1-4 illustrate an aspirin transdermal patch 10 in accordance with the present invention and the related features. The absence of shading in the Figures in no way reflects the presence or absence of a particular characteristic of the patch.
  • the aspirin transdermal patch 10 includes an outer layer 12, a vapor impermeable layer 14, a vapor permeable layer 16, an aspirin containing layer 18, adhesive portions 20, and a peelable liner 22.
  • the outer layer 12 of the present invention is made of polyester or other suitable material now known or heretofore developed in the art.
  • the outer layer 12 is approximately 0.1mm to 1.0mm in thickness.
  • the outer layer 12 must be of sufficient mechanical strength in order to resist exposure to water and minimal physical touching, such as the brushing of a hand or clothing against the surface of the outer layer 12.
  • the outer layer 12 may be translucent or opaque and should provide a suitable surface for the printing of indicia upon it.
  • the vapor impermeable layer 14 of the present invention is made of vapor deposited aluminum or other suitable material now known or heretofore developed in the art.
  • the vapor impermeable layer 14 is approximately 0.01mm to 0.10mm in thickness.
  • the vapor permeable layer 16 of the present invention is made of heat sealing polyethylene or other suitable material now known or heretofore developed in the art.
  • the vapor permeable layer 16 is approximately 0.01mm to 0.10mm in thickness.
  • the vapor permeable layer 16 allows moisture to escape out of the sides of the patch. This vapor escape function minimizes the entrapment of moisture on the skin surface of the patient wearing the patch of the present invention and, hence, decreases the "pruning" of the skin and skin irritation.
  • the aspirin layer 18 of the present invention is comprised of microcrystalline aspirin and polyurethane foam or other suitable material now known or heretofore developed in the art.
  • the aspirin layer 18 is approximately 0.1mm to 1.0mm in thickness.
  • Aspirin or thioaspirin may be present in the aspirin layer 18.
  • the aspirin component is present in the open cells of the polymer. Moisture provided from the skin of the patient hydrates the polymer foam, which allows the aspirin to escape from the polymer foam and enter the transdermal surface of the patient's skin.
  • the adhesive portions 20 of the present invention are conventional adhesives now known or heretofore developed in the art.
  • the adhesive 20 is used not only to connect the layers to one another, but also to provide a means for adhering the aspirin transdermal patch to a patient's skin surface.
  • the adhesive 20 should provide a strong fixation of the patch on the skin, but should also be able to allow removal of the patch by the patient. In other words, the patch is not meant to be permanently affixed to a patient's body.
  • the peelable liner 22 of the present invention is constructed of a clear or opaque plastic material which is impervious to the pharmaceutical composition.
  • the adhesive portions 22 are not to contact the aspirin contained in the polymer of the aspirin layer 18.
  • One way to accomplish this is illustrated in Figs. 1-3. As shown in Fig.
  • the patch 10 of the present invention although illustrated in the Figs, as square, may be made of any shape or size.
  • the patch may be spherical, triangular, rectangular, etc. It may also be designed to fit a particular area of the body. For example, it can be larger in size to provide localized relief for back pain.
  • the patch may be used to provide aspirin to a patient for analgesic, antipyretic, anti-inflammatory, Kawasaki disease (children), antirheumatic, transient ischemic attack prophylaxis, or myocardial infarction prophylaxis
  • the amount of aspirin in the patch can be dictated by the projected use of the patch.
  • the patch may be designed to provide controlled or immediate release of aspirin to a patient.
  • the patch may be worn by a patient for hours, a day, or multiples of days, depending on the intended use and the aspirin release in the patch.
  • other pharmaceutical compounds may be included in the patch.
  • drugs that are compatible with aspirin they may be contained along with the aspirin in the polymer.
  • the aspirin could be contained in one cell with the polymer, another drug in a second cell, and so forth.

Abstract

L'invention concerne un timbre transdermique d'aspirine qui présente une couche externe, une couche imperméable à la vapeur, une couche perméable à la vapeur, une couche contenant de l'aspirine, des parties adhésives et une doublure pelable.
PCT/US2005/006297 2004-02-27 2005-02-25 Timbre transdermique d'aspirine WO2005084255A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54844704P 2004-02-27 2004-02-27
US60/548,447 2004-02-27
US6569705A 2005-02-24 2005-02-24
US11/065,697 2005-02-24

Publications (2)

Publication Number Publication Date
WO2005084255A2 true WO2005084255A2 (fr) 2005-09-15
WO2005084255A3 WO2005084255A3 (fr) 2006-02-02

Family

ID=34922104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006297 WO2005084255A2 (fr) 2004-02-27 2005-02-25 Timbre transdermique d'aspirine

Country Status (1)

Country Link
WO (1) WO2005084255A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912643A1 (fr) * 2007-02-15 2008-08-22 Dbv Technologies Sa Patch pour application cutanee
WO2011076401A1 (fr) 2009-12-23 2011-06-30 Holger Schankin Compositions pharmaceutiques sensiblement exemptes d'eau, contenant de l'acide acétylsalicylique
ITUB20153407A1 (it) * 2015-09-04 2017-03-04 Elena Poli Dispositivo medicale per il trattamento delle infezioni cutanee da hpv
WO2017037684A1 (fr) * 2015-09-04 2017-03-09 Poli Md S.R.L. Composition et dispositif médical comprenant de l'acide acétylsalicylique pour le traitement d'infections cutanées par le papillomavirus humain
ITUA20163415A1 (it) * 2016-05-13 2017-11-13 Poli Md S R L Dispositivo medicale per il trattamento delle infezioni cutanee da hpv
US11202826B2 (en) 2007-12-03 2021-12-21 Dbv Technologies Allergen desensitization method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268355B1 (en) * 1997-06-25 2001-07-31 Teikoku Seiyaku Co., Ltd. Stable aspirin-containing preparations for external use
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268355B1 (en) * 1997-06-25 2001-07-31 Teikoku Seiyaku Co., Ltd. Stable aspirin-containing preparations for external use
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104720A2 (fr) * 2007-02-15 2008-09-04 Dbv Technologies Patch pour application cutanee
WO2008104720A3 (fr) * 2007-02-15 2008-10-23 Dbv Tech Patch pour application cutanee
US8287899B2 (en) 2007-02-15 2012-10-16 Dbv Technologies Patch for cutaneous application
FR2912643A1 (fr) * 2007-02-15 2008-08-22 Dbv Technologies Sa Patch pour application cutanee
US11202826B2 (en) 2007-12-03 2021-12-21 Dbv Technologies Allergen desensitization method
US11931411B2 (en) 2007-12-03 2024-03-19 Dbv Technologies Allergen desensitization method
WO2011076401A1 (fr) 2009-12-23 2011-06-30 Holger Schankin Compositions pharmaceutiques sensiblement exemptes d'eau, contenant de l'acide acétylsalicylique
WO2017037684A1 (fr) * 2015-09-04 2017-03-09 Poli Md S.R.L. Composition et dispositif médical comprenant de l'acide acétylsalicylique pour le traitement d'infections cutanées par le papillomavirus humain
CN107921049A (zh) * 2015-09-04 2018-04-17 波利摩迪股份公司 用于治疗人乳头状瘤病毒皮肤感染的含乙酰水杨酸的组合物和医疗装置
KR20180043799A (ko) * 2015-09-04 2018-04-30 폴리 엠디 에스.알.엘. 인유두종 바이러스 피부 감염의 치료를 위한 아세틸살리실산을 포함하는 조성물 및 의료 장치
AU2016314621B2 (en) * 2015-09-04 2021-05-13 Poli Md S.R.L. Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections
CN115089595A (zh) * 2015-09-04 2022-09-23 波利摩迪股份公司 用于治疗人乳头状瘤病毒皮肤感染的含乙酰水杨酸的组合物和医疗装置
KR102591220B1 (ko) * 2015-09-04 2023-10-18 폴리 엠디 에스.알.엘. 인유두종 바이러스 피부 감염의 치료를 위한 아세틸살리실산을 포함하는 조성물 및 의료 장치
ITUB20153407A1 (it) * 2015-09-04 2017-03-04 Elena Poli Dispositivo medicale per il trattamento delle infezioni cutanee da hpv
ITUA20163415A1 (it) * 2016-05-13 2017-11-13 Poli Md S R L Dispositivo medicale per il trattamento delle infezioni cutanee da hpv

Also Published As

Publication number Publication date
WO2005084255A3 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
JP2513712B2 (ja) 創傷用ドレッシング
FI79467B (fi) Nytt bandage foer administrering av ett laekemedel.
JP2620789B2 (ja) 活性物質の経口投与製剤
ES2205460T3 (es) Un aposito, metodo de fabricar un aposito y uso de un aposito.
US6120792A (en) Medicated skin patch and method for its use
US5464610A (en) Method for treating onychomycosis
KR100267359B1 (ko) 항혈전성 치료 및 암 예방을 위한 아세틸살리실산을 함유하는 경피 투여 시스템
ES2386730T3 (es) Procedimiento de producción de un parche adhesivo
ES2044206T3 (es) Procedimiento para la obtencion de un sistema terapeutico transdermal en forma de un emplasto con varias capas.
WO2005084255A2 (fr) Timbre transdermique d'aspirine
JPS59186564A (ja) 投薬装置
ES2052656T3 (es) Una formulacion de revestimiento para la encapsulacion de sustancias bioactivas.
JPS59155268A (ja) 薬剤注入装置
MXPA96004352A (en) Topical bandage, method of manufacturing of topical unvendage and use of a bandage top
US4765986A (en) Medicinal plaster for systemic use
US5863941A (en) Method and composition of a topical treatment of inner ear and labyrinth symptoms
US6086912A (en) Topical drug delivery system
US4788064A (en) Transdermal delivery system
CA2480683A1 (fr) Unite de liaison de systemes therapeutiques transdermiques separables individuellement
KR830001816B1 (ko) 중합형 확산성 매트릭스의 제조방법
JPS63297320A (ja) 複合貼付製剤
SK16952000A3 (sk) Laminát na priloženie na akceptor
JP3799502B2 (ja) 抗血栓治療および癌予防のためのアセチルサリチル酸を含有する経皮投与システム
US20050118245A1 (en) Assembled unit consisting of individually separable, transdermal, therapeutic systems
JPS63130529A (ja) 複合貼付製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase